Advertisement

Advanced Cell Technology Inc. has won two patents related to its stem cell-derived regenerative technology used to treat eye disorders.

The Marlborough company was granted one patent to use human retinal pigment epithelial (RPE) cells differentiated from human embryonic stem cells to treat retinal degeneration, including Stargardt’s disease, retinitis pigmentosa and macular degeneration. The second patent covers ACT’s method of manufacturing RPE cells from human embryonic stem cells for the purpose of transplanting the cells as treatment.

SOURCE

Advertisement
Advertisement